Building Upon Solid Foundations

Innoviva’s royalty portfolio is anchored by its flagship partnership with Glaxo Group Limited (GSK), which include RELVAR®/BREO® ELLIPTA®, ANORO® ELLIPTA®, and TRELEGY® ELLIPTA®.

 

Approved for COPD/Asthma and marketed globally.

RELVAR®/BREO® ELLIPTA®

Royalty Structure

Innoviva receives royalties on net sales of RELVAR®/BREO® ELLIPTA® of 15% for the first $3.0 billion of annual global net sales and 5% for all annual global net sales above $3.0 billion.

In addition, Innoviva retains a 15% economic interest in future payments made by GSK for earlier-stage programs.

Approved for COPD and marketed globally.

ANORO® ELLIPTA® (UMEC/VI)

Royalty Structure

Innoviva receives royalties on net sales of ANORO® ELLIPTA® (and other potential products with a LABA from LABA collaboration) with upward tiering of 6.5% to 10% of annual global net sales.